GLP-1 RA Reduces Severity of Steatotic Liver Disease in People With HIV
By Elana Gotkine HealthDay Reporter
MONDAY, March 18, 2024 -- For people with HIV (PWH) with metabolic-associated steatotic liver disease (MASLD), semaglutide is associated with absolute and relative declines in intrahepatic triglyceride (IHTG) content, according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 3 to 6 in Denver.
Jordan E. Lake, M.D., from the University of Texas at Houston, and colleagues designed a phase 2b, single-arm, pilot study to examine the effects of semaglutide on magnetic resonance imaging-proton density fat fraction-quantified IHTG content in PWH and MASLD. Adult PWH on suppressive antiretroviral therapy with central adiposity, insulin resistance, or prediabetes and SLD received semaglutide for 24 weeks (49 participants).
The researchers found that semaglutide was well tolerated, with only two grade 3 and no grade 4 possibly related adverse events reported. The mean baseline IHTG was 12.7 percent; mean absolute and relative declines were –4.2 and –31.3 percent, respectively. Overall, 29 percent of participants had complete resolution of MASLD (absolute IHTG <5 percent), and 58 percent had a relative reduction of IHGT of ≥30 percent. For women, Hispanics, non-Hispanic Whites, and individuals with increasing age, there were trends seen toward greater improvements in IHTG. There were also significant improvements noted in weight, waist circumference, fasting glucose, and triglyceride concentrations. There was a correlation seen between improvements in IHTG and weight loss on semaglutide.
"Low-dose (1 mg weekly) semaglutide is a safe and effective pharmacologic therapy for MASLD in PWH and shows evidence of broader cardiometabolic benefit," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Mailed HIV Self-Tests Can Improve Access to Testing in Priority Audiences
THURSDAY, June 20, 2024 -- Mailed HIV-self tests (HIVSTs) can increase testing among persons who have never received testing for HIV or have not received testing in the past year...
Survodutide Tied to Significant Improvement in Fatty Liver Disease
MONDAY, June 17, 2024 -- Most patients taking survodutide, a dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, experience significant improvement in...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.